Drugs / CNP520
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02576639 | Aug 2015 → Mar 2016 | Alzheimer disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT03131453 | Aug 2017 → Mar 2020 | Alzheimer disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2/3 | NCT02565511 | Nov 2015 → Apr 2020 | Alzheimer disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-07-11 | Novartis Pharmaceuticals | Results Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention novartis.com ↗
An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function. |
| 2019-07-11 | Amgen | Results Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention amgen.com ↗
Amgen (NASDAQ:AMGN), Novartis and Banner Alzheimer's Institute today announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in two pivotal Phase 2/3 studies in the Alzheimer's Prevention Initiative Generation Program. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-07-11 | Novartis Pharmaceuticals | Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention novartis.com ↗ |
| 2019-07-11 | Amgen | Amgen, Novartis And Banner Alzheimer's Institute Discontinue Clinical Research Program With BACE Inhibitor CNP520 For Alzheimer's Prevention amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNP520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576639 ↗ |
| Route | Oral | “CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.” NCT02565511 ↗ |